NCT03023722 2021-10-28Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic CancerYale UniversityPhase 2 Completed18 enrolled 10 charts
NCT02610140 2020-11-04Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)BayerPhase 2 Completed248 enrolled 23 charts